0001179110-21-010165.txt : 20211116
0001179110-21-010165.hdr.sgml : 20211116
20211116160233
ACCESSION NUMBER: 0001179110-21-010165
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211112
FILED AS OF DATE: 20211116
DATE AS OF CHANGE: 20211116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Young Diane C.
CENTRAL INDEX KEY: 0001648010
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-15006
FILM NUMBER: 211416010
MAIL ADDRESS:
STREET 1: 175 TOYOTA PLAZA, 7TH FLOOR
CITY: MEMPHIS
STATE: TN
ZIP: 38103
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Celldex Therapeutics, Inc.
CENTRAL INDEX KEY: 0000744218
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 133191702
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
BUSINESS PHONE: 908-200-7500
MAIL ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
FORMER COMPANY:
FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC
DATE OF NAME CHANGE: 19980828
FORMER COMPANY:
FORMER CONFORMED NAME: T CELL SCIENCES INC
DATE OF NAME CHANGE: 19920703
4
1
edgar.xml
FORM 4 -
X0306
4
2021-11-12
0
0000744218
Celldex Therapeutics, Inc.
CLDX
0001648010
Young Diane C.
C/O CELLDEX THERAPEUTICS, INC.
53 FRONTAGE ROAD, SUITE 220
HAMPTON
NJ
08827
0
1
0
0
SVP, Chief Medical Officer
Common Stock
2021-11-12
4
M
0
4600
10.38
A
6715
D
Common Stock
2021-11-12
4
S
0
4600
42.9411
D
2115
D
Incentive Stock Option (Right to Buy)
10.38
2021-11-12
4
M
0
4600
0.00
D
2030-06-18
Common Stock
4600
67400
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.6400 to $43.2000 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
/s/ Sam Martin, attorney-in-fact for Diane C. Young
2021-11-16